Global Acromegaly and Gigantism Drugs Market 2018-2022

末端肥大症・巨人症治療薬の世界市場2018-2022:ソマトスタチン類縁体、GH受容体遮断薬、ドパミン受容体刺激薬、組換えヒトIGF-1

◆タイトル:Global Acromegaly and Gigantism Drugs Market 2018-2022
◆商品コード:IRTNTR20504
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年2月9日
◆ページ数:100
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、末端肥大症・巨人症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、末端肥大症・巨人症治療薬の世界市場規模及び予測、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。Technavio社は末端肥大症・巨人症治療薬の世界市場が2018-2022年期間中に年平均3.03%成長すると予測しています。当レポート上に記載されている主な企業は、Ipsen 、Novartis、Pfizer等です。

About Acromegaly and Gigantism DrugsThe acromegaly and gigantism are GH-related diseases. Acromegaly disease occurs in adults while gigantism occurs in children.

Technavio’s analysts forecast the global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global acromegaly and gigantism drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of acromegaly and gigantism drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Acromegaly and Gigantism Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Ipsen
• Novartis
• Pfizer

[Market driver]
• Strong pipeline
• For a full, detailed list, view our report

[Market challenge]
• Difficulty in diagnosis
• For a full, detailed list, view our report

[Market trend]
• Growing popularity of drugs over surgeries
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing
• Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY DRUG CLASS
• Segmentation by drug class
• Comparison by drug class
• Somatostatin analogs – Market size and forecast 2017-2022
• GH receptor antagonists – Market size and forecast 2017-2022
• Dopamine agonists – Market size and forecast 2017-2022
• Recombinant human IGF-1 – Market size and forecast 2017-2022
• Market opportunity by product

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 14: MARKET TRENDS
• Growing popularity of drugs over surgeries
• Focus on long-acting novel formulations

PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Ipsen
• Novartis
• Pfizer

PART 17: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Parent market
Exhibit 02: Global acromegaly and gigantism drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global acromegaly and gigantism drugs market 2017-2022 ($ mn)
Exhibit 09: Global acromegaly and gigantism drugs market: Year-over-year (YoY) growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials for global acromegaly and gigantism drugs market
Exhibit 20: Segmentation of global acromegaly and gigantism drugs market by drug class 2017-2022 (%)
Exhibit 21: Comparison by drug class
Exhibit 22: Somatostatin analogs – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Somatostatin analogs – YoY growth 2018-2022 (%)
Exhibit 24: GH receptor antagonists – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: GH receptor antagonists – YoY growth 2018-2022 (%)
Exhibit 26: Dopamine agonists – Market size and forecast 2017-2022 ($ mn)
Exhibit 27: Dopamine agonists – YoY growth 2018-2022 (%)
Exhibit 28: Recombinant human IGF-1 – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Recombinant human IGF-1 – YoY growth 2018-2022 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Segmentation of global acromegaly and gigantism drugs market by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Americas – YoY growth 2018-2022 (%)
Exhibit 36: Top three countries in Americas
Exhibit 37: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 38: EMEA – YoY growth 2018-2022 (%)
Exhibit 39: Top three countries in EMEA
Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC – YoY growth 2018-2022 (%)
Exhibit 42: Top three countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Percentage increase in GDI of India, China, and US for 2011-2016
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Ipsen – Vendor overview
Exhibit 51: Ipsen – Business segments
Exhibit 52: Ipsen – Organizational developments
Exhibit 53: Ipsen – Geographic focus
Exhibit 54: Ipsen – Segment focus
Exhibit 55: Ipsen – Key offerings
Exhibit 56: Ipsen– Key customers
Exhibit 57: Novartis – Vendor overview
Exhibit 58: Novartis – Business segments
Exhibit 59: Novartis – Organizational developments
Exhibit 60: Novartis – Geographic focus
Exhibit 61: Novartis – Segment focus
Exhibit 62: Novartis – Key offerings
Exhibit 63: Pfizer – Vendor overview
Exhibit 64: Pfizer – Business segments
Exhibit 65: Pfizer – Organizational developments
Exhibit 66: Pfizer – Geographic focus
Exhibit 67: Pfizer – Segment focus
Exhibit 68: Pfizer – Key offerings
Exhibit 69: Pfizer – Key customers



【掲載企業】

Ipsen, Novartis, and Pfizer

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[末端肥大症・巨人症治療薬の世界市場2018-2022:ソマトスタチン類縁体、GH受容体遮断薬、ドパミン受容体刺激薬、組換えヒトIGF-1] (Global Acromegaly and Gigantism Drugs Market 2018-2022 / IRTNTR20504)販売に関する免責事項
[末端肥大症・巨人症治療薬の世界市場2018-2022:ソマトスタチン類縁体、GH受容体遮断薬、ドパミン受容体刺激薬、組換えヒトIGF-1] (Global Acromegaly and Gigantism Drugs Market 2018-2022 / IRTNTR20504)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆